BioMedNewsBreaks

ThursdayMar 19, 2026 10:45 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights HyBryte Clinical Data In Peer-Reviewed Journal Publication

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma has been published in the peer-reviewed journal Expert Opinion on Investigational Drugs, highlighting the therapy’s safety profile, non-mutagenic mechanism and demonstrated efficacy across studies, while supporting its potential as a first-line treatment option as the company advances its ongoing FLASH2 Phase 3 trial with interim analysis expected in the second quarter of 2026. To view the full press release, visit https://ibn.fm/9E41P About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is…

Continue Reading

ThursdayMar 19, 2026 10:32 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured On BioMedWire Podcast Highlighting Phase 3 HyBryte Progress And Key Inflection Points

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, was featured in the latest BioMedWire Podcast episode where CEO Christopher Schaber discussed the upcoming interim analysis of the Phase 3 FLASH2 study evaluating HyBryte(TM) for cutaneous T-cell lymphoma, noting strong blinded aggregate response rates above initial assumptions and outlining potential outcomes including early study completion or continued enrollment, while emphasizing upcoming interim and top-line data as potentially transformational milestones supporting commercialization and partnership opportunities.  To view the full press release, visit https://ibn.fm/wYVlS About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.…

Continue Reading

ThursdayMar 19, 2026 9:50 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Partners With NeuroRPM To Integrate AI Platform In Parkinson Study

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a partnership with NeuroRPM to implement an FDA-cleared AI platform in its ongoing Parkinson’s disease study, enabling real-time monitoring of symptoms such as bradykinesia, tremor and dyskinesia through wearable and mobile technology, with the data serving as digital biomarkers to enhance disease tracking, support evaluation of buntanetap over the 36-month trial and provide deeper insights into treatment response and future clinical development. To view the full press release, visit https://ibn.fm/iqVYf About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing…

Continue Reading

WednesdayMar 18, 2026 10:50 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Secures Costa Rica Approval for Kinesiology Tape Line 

Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health has approved its line of kinesiology tapes for import and sale, with exclusive distribution partner Innomedica CCB overseeing and financing the regulatory process. The company plans to ramp up marketing efforts in partnership with Innomedica, targeting both its kinesiology tape products and mosquito repellent patch line following the approval. To view the full press release, visit https://ibn.fm/LmF4t About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal…

Continue Reading

TuesdayMar 17, 2026 11:44 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product 

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA’s Bioequivalence Program stating no bioequivalence deficiencies were identified at this time in its Abbreviated New Drug Application, with a preliminary determination ahead of anticipated approval in Summer 2026. The company highlighted its preservative-free ketamine formulation, which excludes benzethonium chloride, as a potential advancement in safety and stability, while continuing to pursue regulatory pathways for broader therapeutic use. To view the full press release, visit https://ibn.fm/fNDMM About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic…

Continue Reading

MondayMar 16, 2026 9:10 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced that minutes from a Type C meeting with the U.S. Food and Drug Administration support the agency’s willingness to review a New Drug Application for NRX-100, a preservative-free ketamine formulation, based on existing clinical trial data demonstrating substantial evidence of effectiveness without requiring additional clinical trials. The company said the FDA also confirmed openness to reviewing Real World Evidence as confirmatory data and indicated no additional nonclinical or bridging studies would be required, while NRx plans to pursue a primary indication for treating severe depression in patients who may experience suicidal ideation and continues to…

Continue Reading

FridayMar 13, 2026 9:20 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4 and Full-Year 2025 Results, Highlights Launch of TONMYA(TM)

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, reported financial results for the fourth quarter and full year ended Dec. 31, 2025, highlighting the U.S. launch of TONMYA(TM), the first new medicine approved for fibromyalgia in more than 15 years. The product, approved by the U.S. Food and Drug Administration in August 2025, became commercially available by prescription on Nov. 17, 2025, and early launch metrics indicate growing prescriber uptake, with more than 1,500 healthcare providers prescribing the therapy and approximately 2,500 patients initiating treatment. Tonix also advanced several pipeline programs during the year, including in-licensing TNX-4800 for…

Continue Reading

FridayMar 13, 2026 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q4 and Full-Year 2025 Results, Advances Commercialization and Clinical Development

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, reported financial and operational results for the fourth quarter and full year ended Dec. 31, 2025, highlighting progress toward commercialization following U.S. Food and Drug Administration ("FDA") 510(k) clearance of its 12-lead electrocardiogram ("ECG") synthesis software in December 2025. The company has initiated a limited market launch targeting concierge and preventive cardiology groups and secured its first commercial partnership with ClearCardio(TM), while also enrolling initial patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. Additional developments include completion…

Continue Reading

WednesdayMar 11, 2026 12:17 pm

BioMedNewsBreaks — Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) Reports 99.67% Share Redemptions Ahead Of VERAXA Biotech Merger

Voyager Acquisition (NASDAQ: “VACHU,” “VACH,” “VACHW”) announced that holders of 25,217,315 Class A ordinary shares — representing approximately 99.67% of the shares outstanding — exercised their redemption rights in connection with the company’s planned business combination with VERAXA Biotech AG. Following the redemptions, approximately $885,556 will remain in Voyager’s trust account and 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG, with the combined company expected to trade on Nasdaq under the ticker “VRXA” upon completion of the transaction. To view the full press release, visit https://ibn.fm/Y6KAF About Voyager Acquisition Corp. Voyager is a special purpose acquisition company with a bold…

Continue Reading

WednesdayMar 11, 2026 9:50 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Explores CNS Asset Acquisitions To Expand Brain Health Pipeline

Oragenics (NYSE American: OGEN) announced it is exploring potential acquisitions of additional central nervous system assets focused on brain health and brain recovery indications that align with its proprietary intranasal drug delivery platform and lead candidate ONP-002. The company said the initiative complements its existing AI-enabled drug discovery collaboration with Receptor.AI and is intended to build a diversified CNS pipeline, while ONP-002 continues advancing through Phase IIa clinical trials in Australia targeting concussion and mild traumatic brain injury with plans for U.S. Phase IIb studies following a future IND submission. To view the full press release, visit https://ibn.fm/S8Srs About Oragenics,…

Continue Reading